Get the Stockscreener App
0.4723
1.68%
0.0078
After Hours:
.46
-0.0123
-2.60%
Century Therapeutics Inc stock is traded at $0.4723, with a volume of 962.78K.
It is up +1.68% in the last 24 hours and down -15.62% over the past month.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
See More
Previous Close:
$0.4645
Open:
$0.48
24h Volume:
962.78K
Relative Volume:
1.07
Market Cap:
$40.80M
Revenue:
$2.24M
Net Income/Loss:
$-136.67M
P/E Ratio:
-0.2062
EPS:
-2.29
Net Cash Flow:
$-102.08M
1W Performance:
-11.69%
1M Performance:
-15.62%
6M Performance:
-3.43%
1Y Performance:
-62.52%
1-Day Range:
$0.451
$0.4849
1-Week Range:
$0.451
$0.58
52-Week Range:
$0.3418
$1.83
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
215-981-4000
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
0.4723 | 40.13M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
Century Therapeutics unveils β islet program for type 1 diabetes - BioWorld MedTech
Century Therapeutics Inc. stock trend outlook and recovery path2025 Technical Overview & Weekly High Return Forecasts - newser.com
Century Therapeutics Reports Positive Q3 2025 Earnings - TipRanks
Real time pattern detection on Century Therapeutics Inc. stockIPO Watch & Safe Capital Growth Trade Ideas - newser.com
Century Therapeutics Inc. stock trendline breakdownPortfolio Growth Summary & Daily Technical Stock Forecast Reports - newser.com
Century Therapeutics unveils T1D therapy program with immune evasion tech By Investing.com - Investing.com Nigeria
Century Therapeutics Shrinks Costs But Net Loss Widens - Finimize
Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Investing News Network
[8-K] Century Therapeutics, Inc. Reports Material Event | IPSC SEC FilingForm 8-K - Stock Titan
Century Therapeutics Q3 net loss widens, despite lower costs - MarketScreener
Century Therapeutics, Inc. SEC 10-Q Report - TradingView
[10-Q] Century Therapeutics, Inc. Quarterly Earnings Report | IPSC SEC FilingForm 10-Q - Stock Titan
Century Therapeutics (NASDAQ: IPSC) unveils beta islet; IND-enabling by 2025, IND in 2026 - Stock Titan
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes - The Manila Times
Century Therapeutics unveils T1D therapy program with immune evasion tech - Investing.com India
Century (NASDAQ: IPSC) unveils CNTY-813 iPSC beta islets; IND-enabling start 2025, IND 2026 - Stock Titan
Analyzing drawdowns of Century Therapeutics Inc. with statistical toolsWeekly Profit Report & Verified Stock Trade Ideas - newser.com
What machine learning models say about Century Therapeutics Inc.2025 Risk Factors & Expert Approved Trade Ideas - newser.com
Ready to Jump After Recent Trade: Century Therapeutics Inc (IPSC) - setenews.com
What Fibonacci levels say about Century Therapeutics Inc. rebound2025 Trading Recap & Daily Profit Maximizing Tips - newser.com
What does recent volatility data suggest for Century Therapeutics Inc.Stock Surge & Reliable Momentum Entry Alerts - newser.com
Is Century Therapeutics Inc a good long term investmentEconomic Data Impact & Minimal Investment Capital - earlytimes.in
Published on: 2025-11-10 05:09:59 - newser.com
How Century Therapeutics Inc. stock performs in rising dollar environment2025 Market Sentiment & Fast Entry High Yield Tips - newser.com
Century Therapeutics Inc. stock momentum explainedMarket Risk Summary & Technical Pattern Based Signals - newser.com
How to manage a losing position in Century Therapeutics Inc.Trade Exit Summary & AI Powered Buy/Sell Recommendations - newser.com
What drives Century Therapeutics Inc stock priceCapital Gains Strategies & Discover Stocks Experts Are Watching - earlytimes.in
What technical signals suggest for Century Therapeutics Inc. stock2025 Breakouts & Breakdowns & Technical Pattern Recognition Alerts - newser.com
Visual analytics tools that track Century Therapeutics Inc. performanceJobs Report & Fast Entry Momentum Trade Alerts - newser.com
Published on: 2025-11-06 01:22:48 - newser.com
Is Century Therapeutics Inc. stock a safe haven asset2025 Geopolitical Influence & Verified Trade Idea Suggestions - Fundação Cultural do Pará
Can volume confirm reversal in Century Therapeutics Inc.2025 EndofYear Setup & Trade Opportunity Analysis - newser.com
Century Therapeutics Inc Stock (IPSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):